KR20140066124A - 점도가 감소된 제제 - Google Patents

점도가 감소된 제제 Download PDF

Info

Publication number
KR20140066124A
KR20140066124A KR1020137029164A KR20137029164A KR20140066124A KR 20140066124 A KR20140066124 A KR 20140066124A KR 1020137029164 A KR1020137029164 A KR 1020137029164A KR 20137029164 A KR20137029164 A KR 20137029164A KR 20140066124 A KR20140066124 A KR 20140066124A
Authority
KR
South Korea
Prior art keywords
formulation
viscosity
ser
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137029164A
Other languages
English (en)
Korean (ko)
Inventor
미르나 에이. 몬크
맨 이 왕
카이 장
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20140066124A publication Critical patent/KR20140066124A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020137029164A 2011-04-07 2012-04-06 점도가 감소된 제제 Withdrawn KR20140066124A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
KR20140066124A true KR20140066124A (ko) 2014-05-30

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029164A Withdrawn KR20140066124A (ko) 2011-04-07 2012-04-06 점도가 감소된 제제

Country Status (12)

Country Link
US (1) US20140044727A1 (enExample)
EP (1) EP2694708A4 (enExample)
JP (1) JP2014510152A (enExample)
KR (1) KR20140066124A (enExample)
CN (1) CN103582724A (enExample)
AU (1) AU2012243126A1 (enExample)
BR (1) BR112013025845A2 (enExample)
CA (1) CA2832560A1 (enExample)
EA (1) EA201391489A1 (enExample)
IL (1) IL228626A0 (enExample)
SG (1) SG193964A1 (enExample)
WO (1) WO2012141978A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180082971A (ko) * 2017-01-11 2018-07-19 (주)셀트리온 안정한 액체 제제
KR20190140464A (ko) * 2017-04-28 2019-12-19 암젠 인크 인간 항-rankl 항체 제형 및 이의 이용 방법

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088120A1 (en) * 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
EA201391488A1 (ru) * 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
US20150150979A1 (en) * 2012-06-21 2015-06-04 Ucb Pharma, S.A. Pharmaceutical formulation
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
MX391067B (es) 2014-10-01 2025-03-21 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
KR20250086801A (ko) 2015-08-24 2025-06-13 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3064859A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CA3141857A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
US8409587B2 (en) * 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
WO2007036745A2 (en) * 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PL2515941T3 (pl) * 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Preparat farmaceutyczny zawierający bewacyzumab
WO2011139718A1 (en) * 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180082971A (ko) * 2017-01-11 2018-07-19 (주)셀트리온 안정한 액체 제제
KR20190140464A (ko) * 2017-04-28 2019-12-19 암젠 인크 인간 항-rankl 항체 제형 및 이의 이용 방법

Also Published As

Publication number Publication date
EP2694708A4 (en) 2014-10-01
BR112013025845A2 (pt) 2018-09-04
WO2012141978A2 (en) 2012-10-18
EP2694708A2 (en) 2014-02-12
EA201391489A1 (ru) 2014-02-28
CA2832560A1 (en) 2012-10-18
IL228626A0 (en) 2013-12-31
US20140044727A1 (en) 2014-02-13
JP2014510152A (ja) 2014-04-24
SG193964A1 (en) 2013-11-29
CN103582724A (zh) 2014-02-12
WO2012141978A3 (en) 2012-12-27
AU2012243126A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
KR20140066124A (ko) 점도가 감소된 제제
KR20140018966A (ko) 점도가 감소된 제제
JP6541581B2 (ja) 低濃度抗体製剤
ES2791690T3 (es) Formulaciones liofilizadas
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
JP2022500386A (ja) Ｃｓｆ−１ｒ抗体製剤
CN106659785A (zh) 包含gm‑csf中和化合物的液体制剂
KR20230009897A (ko) 항-IL-23p19 항체를 포함하는 제제, 이의 제조방법 및 용도
JPWO2008029908A1 (ja) 抗体を含有する安定な凍結乾燥医薬製剤
WO2014141149A1 (en) Formulations with reduced viscosity
JP2024539265A (ja) 製剤
CN119095618A (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
AU2022369042A1 (en) Formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid